secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alto Neuroscience, Inc. (ANRO)
CIK:        0001999480
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0001999480-25-000035
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alto Neuroscience Q1 net loss $15.2M; cash $161.3M; key trial readouts on track
-------------------------------------------------------------------------------

- Net loss of $15.2M for Q1 2025 vs $13.4M in Q1 2024; R&D expense flat at $10.0M.
- Cash, cash equivalents and restricted cash of $161.3M as of March 31, 2025, expected to fund operations into 2028.
- ALTO-203 Phase 2 POC MDD trial topline data expected in Q2 2025; ALTO-101 Phase 2 CIAS data in H2 2025.
- ALTO-300 Phase 2b MDD trial data expected mid-2026; ALTO-100 Phase 2b BPD trial data H2 2026.
- At annual meeting, stockholders reelected Husseini Manji as Class I director and ratified Deloitte as auditor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1999480/000199948025000035/0001999480-25-000035-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1999480/000199948025000035/alto-20250513.htm
  HTML page:      https://secwatch.observer/filing/0001999480-25-000035

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer